Ixico Share Discussion Threads

[tomboyb] 28/4/2022 14:53

40p+ coming -

[arthur_lame_stocks] 21/4/2022 18:53

I wonder what CFE's plans for CIP Merchant Capital are now the takeover is a done deal? Will they liquidate all the assets for a profit? If so there is going to be a lot of IXICO stock available at some point sooner or later. I guess if that is the case the price is going nowhere for a while but we'll see.

[owenski] 21/4/2022 08:28

This truly is a great little company......... If you're a director

Nice lifestyle.

Unfortunately the business is niche, focused on rare conditions and not broader applications.

Maybe a takeover target at some point, the chart says it all.

[tomboyb] 21/4/2022 08:21

NT at 38p -

Good 800k contract -

[tomboyb] 21/4/2022 07:33

IXICO plc New Contract Win
21/04/2022 7:00am
UK Regulatory (RNS & others)

Ixico (LSE:IXI)
Intraday Stock Chart

Thursday 21 April 2022

Click Here for more Ixico Charts.
TIDMIXI

RNS Number : 8126I

IXICO plc

21 April 2022

21 April 2022

IXICO plc

("IXICO" or the "Company")

Contract award with a new client for a Huntington's Disease ('HD') trial worth circa GBP800,000

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD. HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.

The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years.

Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication. This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial. This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study.

Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development."

For further information please contact:

[tomboyb] 19/4/2022 13:56

Rising from 52 weeks lows -

[rocketblast] 04/4/2022 08:39

Interesting IXI target Takeover soon.

[km18] 21/2/2022 17:45

...from last year...

Company overview:
Ixico plc provides neuroscience expertise, analysis and global operational support for CNS clinical trials. As a result, we could easily put it into the technology sector, as their specialist neuroscience knowledge and AI-driven innovation provides solutions for sponsors to realize the full power of imaging biomarkers. Their scans observe small changes in brain structure, provide insights on the efficacy of new drugs trialled and monitor patient safety. They are estimating a £120m-£150m addressable imaging market per annum and currently have above 10% of market share. In addition, the  ageing population of the planet would mean the CNS market will expand, with preliminary forecasts of triple increase of dementia cases across the world between 2015 and 2050 (coming from the World Alzheimer report in 2018).
Growth is organic, with virtually zero acquisitions over the past 10 years. IXI is continuously investing in R&D and revenue is seeing a healthy 25% CAGR, and the company has become profitable in 2019. They are sitting on a pile of cash, as the company is debt free and return on capital and on equity are both in the top 10 of the industry.
Lates trading update is the yearly just before the full period results. Things are looking good for this year. They have generated £9.2m of revenue, which is ahead of market expectations (£8.7m). EBITDA is also expected to be ahead of the consensus £1.2m. In addition, they have a strong order book of £18.8m they are, however, balancing the positives with a more neutral expectation for the upcoming FY, where they are expecting a return to more normal growth rates, meaning they forecast lower earnings for 2022. We cannot wait for the yearly results on this one, as trading has been strong this year. Although P/E is high at around 31 on TTM basis if they deliver good profitability the stock might prove to be a good investment in the long-run as they are operating in one of the most crucial for our evolvement industries....

...from WealthOracleAM

[toffeeman] 10/2/2022 17:49

It would only be useful on a car that keeps backfiring

[daicaprice] 10/2/2022 17:11

Would anyone on here be interested in the car reg no IXI 4060?

DC

[40 fathoms] 03/2/2022 10:34

It was clear from this interview that Paul Jordan does not really understand Ixico's market positioning. He is would be right if he were talking about Huntingdon's in isolation, but he was talking about the broader neurodegenerative space. Here their position is not strong and they have significant competition and importantly that includes AD.

I think last week’s RNS confirming the appointment of Dr. Lynne Hughes as an advisor is a confirmation of how they are struggling in these other area. If you were market leader, as Paul Jordan suggests, why would you need such an esteemed expert to help you break in to new areas ?

The other problem is to break in to a new area you need to start with Phase I and these will be small contracts and only when you have a sufficient number of these will you start to pick up Phase II and Phase III. Given many of these trials are long in nature it will take 4 or 5 years until you start to see meaningful revenue. Put another way, if you are already in the clinic you will not take the risk of switching your methodology for Neuroimaging, so that means Ixico need to feed the top of the funnel in these areas where they are not competitive and that means preclinical.

The other point I will make is she will not be cheap and they do not have money to burn. If they lose one of their two big contracts accounting for almost 65% of their backlog then they are in trouble in my view. Time for a reset at the top and where the C suite are way, way, way overpaid.

[brummy_git] 03/2/2022 05:19

Paul Jourdan of Amati Global talks positively about IXICO here (starts 27:00)

www.youtube.com/watch?v=0nJJIpsI9Uo

[skyracer] 20/1/2022 08:26

Heads I win. Tails you lose. Worthless "contracts".

[buywell3] 25/12/2021 01:33

Well said:

buywell thinks that larger Institutional shareholders should take a look at this bonus scheme that the remuneration committee are operating

It has effectively meant that the CEO and the Chairman have doubled their already generous pay

Giulio Cerroni CEO 30th Sep 2020 salary 279,239 bonus 258,421
Giulio Cerroni CEO 30th Sep 2019 salary 215,865 bonus 330,300

Grant Nash ... CFO 30th Sep 2020 salary 149,300 bonus 38,196
Grant Nash ... CFO 30th Sep 2019 salary 59,410 bonus 47,142


For a small cap AIM company this is way too much IMO on top of huge bonus payments both have had decent wage increases why ?






Ixico operates a discretionary bonus scheme that takes account of the underlying financial performance of the Group, meeting KPIs and achieving strategic objectives.

All performance targets are set by the Remuneration Committee.

The award of bonus payments to employees, including Executive Directors, are subject to the Remuneration Committee’s review and approval.

For the year to 30 September 2020, the Remuneration Committee determined that bonus related KPIs and strategic objectives were largely met, resulting in the majority of bonus entitlements being achieved





buywell can't see how this share price performance justifies the remuneration committee to make such awards



II's need to get themselves involved ASAP

Just who is on this Remuneration Committee ?



Can't see the names


dyor imo

[w t tutte] 09/12/2021 05:26

Rocketblast, I am afraid your expectations of revenue growth might be too optimistic. On the last call the company said that if over the next 5 years they were to achieve revenue growth of 100% it would require an acquisition. 100% revenue growth over 5 years is decent but not spectacular (that is 15% pa compounded) and to get to that level they will likely need a CR with everything that entails.

The other thing to keep an eye on is further trial cancellations, they mention the possibility a number of times in the interim report. Two clients represent 70% of revenue (one is 55%) and if one of those was to halt after a futility analysis it would be pretty hard to claw back in any sensible time frame. This concentration will improve over time but is a real risk for the next 18 months

I also think without material improvement in the business the CEO's and CFOs pay should be reviewed. Combined, on a cash basis alone (i.e. before options) the two of them account for over 10% of total revenue if you were to add in the US and UK COO/CBOs then you are getting beyond 18% of revenue. The CEO pulls down in excess of 650k year after year. I think the next 12 months will be the test of the C suite team, if they don't deliver we will see if the Chairman is up to the task of bringing about significant change or selling the business or maybe he is too busy with his role as Chairman of CREO.

[rocketblast] 08/12/2021 16:40

Looking good for a Xmas Rally. Market for IXI is massive and its in a sweet spot with demand rapidly increasing. Lets see RNS on a massive deal and contract this month, some say it will be a game changer for IXI.

[w t tutte] 08/12/2021 07:03

It is a good business but it they have a number of issues they need to address and I am not sure I see that happening. I also don't like to see a @ 2.7 million difference between the EBIDTA number and the taxman's number. The capitalisation last year was very significant and (on this scale) is new.

1) They need to quickly shift their revenue from Huntingdon's towards AD. They dominate in Huntingdon's but have limited exposure in the AD market.

2) They need to demonstrate that the significant R&D spend they are making actually allows them to meaningfully grow revenue rather than maintain their position.

3) They need to get a post marketing surveillance product in to the market. This is where I am most hopeful. If they can adapt Assesa for Aria detection in AD patients they might be on to something. But this is going to require a significant investment but on the plus side would probably be paid for by a Biogen or a Lilly.

4) They need to work on more points of differentiation versus competing products. You will not win against ERT/Bioclinca in areas that are not niche.

[daicaprice] 07/12/2021 13:33

Creeping up nicely.

DC

[volsung] 07/12/2021 13:20

Bought a few for 60 new pence a go

[rocketblast] 07/12/2021 09:26

Market for IXI is massive and its in a sweet spot with demand rapidly increasing. Lets see RNS on a massive deal and contract this month, some say it will be a game changer for IXI.

[rocketblast] 07/12/2021 09:21

Great results Sales and Cashflow strong. IXI will have a rapid rise as expected. I still bet on a takeover at these prices and sure that a number of organisations are looking at IXI. Get ready for liftoff great Products and Services. IXI AI algorithms are a great differentiator and asset.

[arthur_lame_stocks] 07/12/2021 09:04

Cashflow was poor.

[daicaprice] 07/12/2021 07:55

Nobody got any comment on the results, they look encouraging to me as an outsider.

DC

[red ninja] 18/11/2021 17:10

Just looking in trading update it says :-

"Outlook

Benefiting from a strong order book, and an improving business outlook resulting from the initiation of new neuroimaging clinical trials during the 2022 financial year, the Company expects a return to revenue growth, albeit at a lower rate than recent historical levels. In the coming year, the Company will continue to pursue its investment plan to accelerate long-term sustained growth. Due to these investments, and the one-time beneficial impacts on EBITDA seen in 2021, the Company expects to see lower profitability in 2022."

"HTtps://www.investegate.co.uk/ixico-plc--ixi-/rns/trading-update-for-year-ended-30-september-2021/202110180700063038P/"

Maybe worries about 2022 profitability ?

[shooting_star] 18/11/2021 17:01

stock getting smashed recently. does anyone have any view as to the driver? now below £30m market cap

feels like an opportunity to top up. not sure why people would be selling at this valuation?